Relapsed/refractory HL: FDG-PET is the trump card

1Citations
Citations of this article
5Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

A number of disease- or host-related markers have been proposed to predict treatment outcome in relapsed/refractory Hodgkin lymphoma (HL). In this issue of Blood, Moskowitz et al demonstrate that fluorodeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography (CT) performed in sequence during second-line treatment recapitulates all of them.1

Cite

CITATION STYLE

APA

Gallamini, A. (2017, November 16). Relapsed/refractory HL: FDG-PET is the trump card. Blood. American Society of Hematology. https://doi.org/10.1182/blood-2017-09-806299

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free